La Inmunoterapia en el manejo del cáncer en el Paraguay

Autor: Tania Fleitas, Maria Liz Paciello

Publikováno v: Revista Paraguaya de Reumatología, Vol 5, Iss 2, Pp 39-42 (2019)

El mundo enfrenta un problema de salud crítico debido al envejecimiento de las sociedades, con estilos de vida poco saludables, desigualdades socioeconómicas y una población mundial en crecimiento. El cáncer se está convirtiendo en uno de los pr

Externí odkaz: https://doaj.org/article/bd820cccb229404790afc99a2d7ca52f

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Autor: Inbal Goldstein, Keith Stockerl-Goldstein, Ella Sorani, Tahir Latif, Gemma Moreno Jiménez, Maria Liz Paciello Coronel, John W. Hiemenz, Abi Vainstein, Árpád Illés, Zachary Crees, Irit Gliko-Kabir, Massimo Martino, Muzaffar H. Qazilbash, Sarah Larson, Udo Holtick, Patrick J. Stiff, Gabor Mikala, Douglas W. Sborov, Giuseppe Milone, Irene García-Cadenas, John F. DiPersio, Nancy M. Hardy, Shaul Kadosh, Ivana N. Micallef, Denise Pereira

Publikováno v: Blood. 138:475-475

Background: Autologous stem cell transplantation (ASCT) in multiple myeloma (MM) has been shown to improve survival compared to conventional chemotherapy alone. However, the ability to perform ASCT relies, in part, on collecting a sufficient number (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a686c39b1f29032b61a0b706fc5c8c7a
https://doi.org/10.1182/blood-2021-144296

Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase:ENEST1st sub-analysis

Autor: Maria Liz Paciello Coronel, Beatrice Vincenzi, Ljubomir Petrov, Fausto Castagnetti, Delphine Rea, Andrzej Hellmann, Francis J. Giles, Andreas Hochhaus, Valentin Garcia-Gutierrez, Maria Asuncion Echeveste Gutierrez, Franҫois-Xavier Mahon, Luca Dezzani, Philipp le Coutre, Gianantonio Rosti, Norbert Gattermann, Nicholas C.P. Cross, Jeroen Janssen

Publikováno v: Hochhaus, A, Mahon, F-X, le Coutre, P, Petrov, L, Janssen, J J W M, Cross, N C P, Rea, D, Castagnetti, F, Hellmann, A, Rosti, G, Gattermann, N, Coronel, M L P, Gutierrez, M A E, Garcia-Gutierrez, V, Vincenzi, B, Dezzani, L & Giles, F J 2017, ' Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase : ENEST1st sub-analysis ', Journal of Cancer Research and Clinical Oncology, vol. 143, no. 7, pp. 1225-1233 . https://doi.org/10.1007/s00432-017-2359-9
Journal of Cancer Research and Clinical Oncology
Journal of Cancer Research and Clinical Oncology, 143(7), 1225-1233. Springer Verlag
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid

PURPOSE: The ENEST1st sub-analysis presents data based on Philadelphia chromosome (Ph) status, i.e., Ph+ and Ph-/BCR-ABL1 + chronic myeloid leukemia.METHODS: Patients received nilotinib 300 mg twice daily, up to 24 months.RESULTS: At screening, 983 p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b32a0b316372c1eb5fd4577816af80c2
https://research.vumc.nl/en/publications/0d7cc258-28f1-462e-bdd2-52e52f3fc3b9